Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig.
- 1 February 1984
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 54 (2), 117-124
- https://doi.org/10.1161/01.res.54.2.117
Abstract
Platelet-activating factor is a novel phospholipid that has been implicated as an important mediator of acute allergic reactions. The intravenous administration of acetyl glyceryl ether phosphorylcholine, a pure, synthetic platelet-activating factor, causes electrocardiographic changes in the rabbit similar to those which are characteristic manifestations of systemic anaphylaxis. To determine whether platelet-activating factor contributes to anaphylactic cardiac dysfunction, we measured platelet-activating factor release from the sensitized guinea pig heart challenged in vitro with specific antigen and compared the resulting cardiac dysfunction with that induced by the injection of acetyl glyceryl ether phosphorylcholine into nonsensitized hearts. The results of these studies document that, during anaphylaxis in the isolated guinea pig heart, a platelet-activating factor is released into the coronary effluent that has physicochemical and functional properties similar to those of acetyl glyceryl ether phosphorylcholine. The intracardiac administration of acetyl glyceryl ether phosphorylcholine (10(-14) to 3 X 10(-9) mol) induced dose-related decreases in left ventricular contractile force (-5 to -85%) and coronary flow (-5 to -85%), as well as impaired atrioventricular conduction. The negative inotropic effect of acetyl glyceryl ether phosphorylcholine also was present in hearts perfused at constant flow. Although, in these hearts, acetyl glyceryl ether phosphorylcholine increased coronary resistance, which may have caused regional shunting and ischemia, it is unlikely that the negative inotropic effect of acetyl glyceryl ether phosphorylcholine was secondary to changes in coronary flow, since acetyl glyceryl ether phosphorylcholine also caused a dose-dependent negative inotropic effect in the electrically paced, noncoronary-perfused left atrium and right ventricular papillary muscle.(ABSTRACT TRUNCATED AT 250 WORDS)This publication has 22 references indexed in Scilit:
- Thromboxane B2 (TxB2) release following acetyl glyceryl ether phosphorylcholine (AGEPC) infusion in the rabbitImmunopharmacology, 1983
- Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.Journal of Clinical Investigation, 1983
- Nonimmunological Production pf Leukotrienes Induced by Platelet-Activating FactorScience, 1982
- The demonstration of histamine release in clinical conditions: A review of past and present assay proceduresKlinische Wochenschrift, 1982
- Cardiac anaphylaxis: SRS-A potentiates and extends the effects of released histamineEuropean Journal of Pharmacology, 1980
- Coronary vasospastic action of thromboxane A2 in isolated, working guinea pig heartsEuropean Journal of Pharmacology, 1978
- Release of 15-keto-13, 14-dihydro-thromboxane B2 and prostaglandin D2 during anaphylaxis as measured by radioimmunoassayNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1978
- Basophil-Derived Platelet-Activating Factor (PAF) as an in Vivo Mediator of Acute Allergic Reactions: Demonstration of Specific Desensitization of Platelets to PAF during IgE-Induced Anaphylaxis in the RabbitThe Journal of Immunology, 1977
- Coronary Tone Modulation: Formation and Actions of Prostaglandins, Endoperoxides, and ThromboxanesScience, 1977
- Quantitative Adsorption of Antibody by the Isolated Heart and the Intensity of Cardiac AnaphylaxisCirculation Research, 1961